Sisu Pharmaceuticals

Sisu Pharma was a clinical-stage biopharmaceutical company focused on the development of treatments for rare diseases, with a primary emphasis on GNE Myopathy (also known as Hereditary Inclusion Body Myopathy). The company's lead product candidate, Ace-ER (aceneuramic acid extended-release), was designed as a substrate replacement therapy to address the underlying sialic acid deficiency in patients with this progressive muscle-wasting disease. Founded in 2014, Sisu Pharma's technology was based on research conducted at the National Institutes of Health (NIH). In February 2017, the company was acquired by Leadiant Biosciences, which sought to integrate Sisu's late-stage program into its existing rare disease portfolio. The acquisition aimed to accelerate the global development and potential commercialization of Ace-ER for patients with limited treatment options. Sisu Pharma's work remains a significant part of the clinical landscape for GNE Myopathy.